Aptevo Therapeutics Inc.
APVONASDAQHealthcare● Active
$4.89
+$0.17(+3.60%)
Market Cap$10693731
P/E Ratio—
52W High$235.98
52W Low$3.8
Aptevo Therapeutics Inc. (APVO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
APVO · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$6.41
Est. -$5.60 · -14.5%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▼ Miss EPS
APVO reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 10, 2026 | -$6.20 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 13, 2026 | -$5.60 | -$6.41 | -14.5% | — | — | — |
| ▲ Q1 FY2026 | Mar 20, 2026 | -$8.09 | $1684.47 | +20921.6% | — | — | — |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$37.59 | -$40.11 | -6.7% | — | — | — |
| ▼ Q3 FY2025 | Aug 11, 2025 | -$0.45 | -$151.08 | -33473.3% | — | — | — |
| ▼ Q2 FY2025 | May 15, 2025 | -$1514.39 | -$1579.14 | -4.3% | — | — | — |
| ▼ Q1 FY2025 | Mar 4, 2025 | -$7.75 | -$82.37 | -962.8% | — | — | — |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$7428.84 | -$6255.86 | +15.8% | — | — | — |
Q3 FY2026
Aug 10, 2026
EPS Actual
—
EPS Est.
-$6.20
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Miss
EPS Actual
-$6.41
EPS Est.
-$5.60
EPS Surpr.
-14.5%
Revenue
—
Q1 FY2026
Mar 20, 2026Beat
EPS Actual
$1684.47
EPS Est.
-$8.09
EPS Surpr.
+20921.6%
Revenue
—
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$40.11
EPS Est.
-$37.59
EPS Surpr.
-6.7%
Revenue
—
Q3 FY2025
Aug 11, 2025Miss
EPS Actual
-$151.08
EPS Est.
-$0.45
EPS Surpr.
-33473.3%
Revenue
—
Q2 FY2025
May 15, 2025Miss
EPS Actual
-$1579.14
EPS Est.
-$1514.39
EPS Surpr.
-4.3%
Revenue
—
Q1 FY2025
Mar 4, 2025Miss
EPS Actual
-$82.37
EPS Est.
-$7.75
EPS Surpr.
-962.8%
Revenue
—
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$6255.86
EPS Est.
-$7428.84
EPS Surpr.
+15.8%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-5.63 | $-5.63 | $-5.63 | 1 |
| Q3 FY2026 | $-5.96 | $-5.96 | $-5.96 | 1 |
| Q2 FY2026 | $-6.20 | $-6.20 | $-6.20 | 1 |
| Q1 FY2026 | $-5.60 | $-5.60 | $-5.60 | 1 |
| Q4 FY2025 | $-5.94 | $-5.94 | $-5.94 | 1 |
| Q3 FY2025 | $-37.62 | $-37.62 | $-37.62 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 13, 2026 | -14.5% | $4.83 | $4.76 | -1.45% |
| ▲ Q1 FY2026 | Mar 20, 2026 | +20921.6% | $4.50 | $4.56 | +1.33% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -6.7% | $25.74 | $26.46 | +2.80% |
| ▼ Q3 FY2025 | Aug 11, 2025 | -33473.3% | $40.68 | $38.70 | -4.87% |
| ▼ Q2 FY2025 | May 15, 2025 | -4.3% | $118.80 | $118.80 | +0.00% |
| ▼ Q1 FY2025 | Mar 4, 2025 | -962.8% | $1,112.40 | $1,062.00 | -4.53% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +15.8% | $3,436.56 | $4,115.88 | +19.77% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +13.5% | $5,541.12 | $5,567.76 | +0.48% |
Q2 FY2026-1.45%
Report Date
May 13, 2026
EPS Beat/Miss
-14.5%
Price Before
$4.83
Price After
$4.76
Q1 FY2026+1.33%
Report Date
Mar 20, 2026
EPS Beat/Miss
+20921.6%
Price Before
$4.50
Price After
$4.56
Q4 FY2025+2.80%
Report Date
Nov 6, 2025
EPS Beat/Miss
-6.7%
Price Before
$25.74
Price After
$26.46
Q3 FY2025-4.87%
Report Date
Aug 11, 2025
EPS Beat/Miss
-33473.3%
Price Before
$40.68
Price After
$38.70
Q2 FY2025+0.00%
Report Date
May 15, 2025
EPS Beat/Miss
-4.3%
Price Before
$118.80
Price After
$118.80
Q1 FY2025-4.53%
Report Date
Mar 4, 2025
EPS Beat/Miss
-962.8%
Price Before
$1,112.40
Price After
$1,062.00
Q4 FY2024+19.77%
Report Date
Nov 7, 2024
EPS Beat/Miss
+15.8%
Price Before
$3,436.56
Price After
$4,115.88
Q3 FY2024+0.48%
Report Date
Aug 8, 2024
EPS Beat/Miss
+13.5%
Price Before
$5,541.12
Price After
$5,567.76
Avg Beat Reaction+7.19%
Avg Miss Reaction-1.61%
Beat Rate3 / 8 quarters
Largest Move+19.77% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: APVO ends December
Aptevo Therapeutics Inc. (APVO) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-6.41 — missing the analyst consensus of $-5.60 by -14.5%. The next APVO earnings date is expected around September 1, 2026.
Each quarter, investors track APVO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. APVO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
APVO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
APVO earnings · 5 questionsAptevo Therapeutics Inc.'s next earnings report is expected around September 1, 2026. APVO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; APVO historically reports after market close (AMC).
APVO earnings datewhen is APVO earningsAPVO next earnings datewhen does APVO report earningsAPVO earnings calendar
▸ Source: FMP · Aptevo Therapeutics Inc. SEC filings · US GAAP · Aptevo Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026